Literature DB >> 8017465

Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.

C A Dujovne1, M H Davidson.   

Abstract

Fluvastatin is a totally synthetic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that is effective in reducing cholesterol when given in a single evening dose. Absorption and rate of bioavailability may be affected when administered with food, but the effect of mealtime dosing on efficacy and safety has not been evaluated. This multicenter, double-blind, placebo-controlled crossover study was performed in 44 patients with primary hypercholesterolemia. Patients received 20 mg of fluvastatin with the evening meal and placebo at bedtime for 6 weeks, followed by 12 weeks of placebo at mealtime and fluvastatin at bedtime (group 1). Group 2 received the opposite treatment schedule, and group 3 received placebo at mealtime and at bedtime for 12 weeks before receiving 20 mg of fluvastatin at bedtime instead of placebo for the final 6 weeks. Fluvastatin with the evening meal resulted in a marginally lower peak serum concentration (p < 0.1) and a significantly delayed time to peak concentration compared with bedtime dosing, but there were no statistically significant differences in the extent of bioavailability. At the end of the first 6 weeks of treatment, similar reductions in low-density lipoprotein (LDL) cholesterol were obtained whether fluvastatin was given at mealtime (-21.8%; p < 0.001) or at bedtime (-23.9%; p < 0.001). After crossover of groups 1 and 2, the results remained constant. With fluvastatin, there were comparable reductions in total cholesterol (p < 0.001) and in LDL:high-density lipoprotein (HDL) ratio (p < 0.001) irrespective of the time of dosing. In conclusion, fluvastatin had a similar tolerability, safety, and efficacy, whether given with the evening meal or at bedtime. There were no serious adverse events nor changes in physical examination findings or laboratory values attributable to treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017465     DOI: 10.1016/0002-9343(94)90230-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.

Authors:  Jose Manuel Izquierdo-Palomares; Jesus Maria Fernandez-Tabera; Maria N Plana; Almudena Añino Alba; Pablo Gómez Álvarez; Inmaculada Fernandez-Esteban; Luis Carlos Saiz; Pilar Martin-Carrillo; Óscar Pinar López
Journal:  Cochrane Database Syst Rev       Date:  2016-11-26

Review 3.  Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.

Authors:  G L Plosker; A J Wagstaff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of fluvastatin.

Authors:  C D Scripture; J A Pieper
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Fluvastatin for lowering lipids.

Authors:  Stephen P Adams; Sarpreet S Sekhon; Michael Tsang; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2018-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.